Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07062588 · ClinicalTrials.gov registry record · Phase 2
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
A Phase 2 study of Osteogenesis Imperfecta (OI), sponsored by Angitia Incorporated Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT07062588: Recruiting Phase 2 study of Osteogenesis Imperfecta (OI), sponsored by Angitia Incorporated Limited.
NCT07062588 is a Phase 2 study of Osteogenesis Imperfecta (OI) that is actively recruiting participants, run by Angitia Incorporated Limited. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07062588, a Phase 2 study of Osteogenesis Imperfecta (OI), is actively recruiting participants, sponsored by Angitia Incorporated Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AGA2115
Study Locations (20)
Other
- Instituto de Investigaciones Metabolicas Dr. Zanchetta - Sede Centro - Buenos Aires
- Monash University-Monash Medical Centre (MMC) - Melbourne
- Royal Melbourne Hospital - Parkville
- Royal North Shore Hospital (RNSH) - Saint Leonards
- Adults Westmead Hospital - Westmead
- Aarhus Universitetshospital - Medicinsk Endokrinologisk Afdeling (MEA) Ambulatoriet - Tage-Hansens Gade - Aarhus
- Odense Universitetshospital - Odense
- Hopital Edouard Herriot - Lyon
- Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Lariboisiere - Paris
Arizona
- Phoenix Children's - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
Delaware
- Nemours/Alfred I. duPont Hospital for Children - Wilmington
Indiana
- Indiana University School of Medicine, Department of Medicine and Pediatrics Division of Endocrinology - Indianapolis
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Nebraska
- University of Nebraska Medical Center (UNMC) - Diabetes and Endocrinology Center - Omaha
New Mexico
- New Mexico Clinical Research & Osteoporosis Center, Inc. (NMCROC) - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
What NCT07062588 shows while recruiting
NCT07062588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Osteogenesis Imperfecta (OI) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07062588 names 20 study sites across 12 states, led by Other, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07062588 about?
NCT07062588 is a clinical study titled "Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)". This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
What is the current status of trial NCT07062588?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-12. Estimated completion is 2029-02.
What conditions does trial NCT07062588 study?
This clinical trial studies the following conditions: Osteogenesis Imperfecta (OI).
What interventions are being tested in trial NCT07062588?
The interventions under investigation include: Placebo (OTHER), AGA2115 (DRUG).
Who is sponsoring clinical trial NCT07062588?
This trial is sponsored by Angitia Incorporated Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07062588 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Delaware, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07062588's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,118 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI